-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LzntXqjt5FWQmVBXIAFXUgVVcGTW/+nOeVnfu/Edr+LugatwEzDMCCS0KHqINS8o
 Xa56X6MQ0EwRDUkbz2NWSQ==

<SEC-DOCUMENT>0000842023-11-000003.txt : 20110201
<SEC-HEADER>0000842023-11-000003.hdr.sgml : 20110201
<ACCEPTANCE-DATETIME>20110201091511
ACCESSION NUMBER:		0000842023-11-000003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110201
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110201
DATE AS OF CHANGE:		20110201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		11561537

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): February 1, 2011

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on February 1,
2011, describing the results of operations for the quarter and six months
ended December 31, 2010 and its financial condition as of December 31,
2010, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and six months
ended December 31, 2010 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated February 1, 2011.

         99.2 Segment information for the quarter and six months
              ended December 31, 2010.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: February 1, 2011               TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated February 1, 2011.

       99.2     Segment information for Techne Corporation for the quarter
                and six months ended December 31, 2010.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release211.txt
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 1, 2011
<TEXT>


            TECHNE CORPORATION RELEASES UNAUDITED SECOND QUARTER
                         RESULTS FOR FISCAL YEAR 2011

Minneapolis/February 1, 2011/ Techne Corporation's (NASDAQ: TECH)
consolidated net earnings for the quarter ended December 31, 2010 increased
7.3% to $26.5 million or $0.71 per diluted share compared with $24.7 million
or $0.66 per diluted share for the quarter ended December 31, 2009.  The
increase in consolidated net earnings for the quarter resulted from an
increase in sales and a decrease in income taxes due to the renewal of the
U.S. research and development credit. The $898,000 benefit ($0.02 per share)
from the renewal of the research and development credit includes $659,000
that relates to the previous three calendar quarters.  For the six months
ended December 31, 2010, Techne's consolidated net earnings increased 2.8% to
$52.9 million or $1.42 per share compared with $51.5 million or $1.38 per
share for the six months ended December 31, 2009.

Consolidated net sales for the quarter and six months ended December 31, 2010
were $67.7 million and $135.7 million, increases of 3.3% and 2.7%,
respectively, from the quarter and six months ended December 31, 2009.
Consolidated net sales for the quarter and six months were negatively
affected by a stronger U.S. dollar as compared to foreign currencies for the
quarter and six months ended December 31, 2009. Excluding the effect of
changes in foreign currency exchange rates, consolidated net sales increased
5.1% and 4.5% for the quarter and six months ended December 31, 2010,
respectively, from the comparable prior-year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $44.4 million for the
quarter ended December 31, 2010, an increase of 4.8% from $42.4 million for
the quarter ended December 31, 2009.  North American biotechnology sales to
industrial pharmaceutical and biotechnology customers increased 3.9% during
the second quarter of fiscal 2011 as compared to the second quarter of fiscal
2010.  Biotechnology sales to academic customers and sales in China grew 6.7%
and 19.2%, respectively, while sales to Pacific Rim distributors declined
4.5%, in the second quarter of fiscal 2011 as compared to the second quarter
of fiscal 2010.  Biotechnology sales for the six months ended December 31,
2010, were $91.1 million, an increase of 5.4% from $86.4 million for the six
months ended December 31, 2009.  North American biotechnology sales to
industrial pharmaceutical and biotechnology customers increased 3.5% during
the six months ended December 31, 2010 as compared to the first six months of
fiscal 2010.  Biotechnology sales to academic customers, to Pacific Rim
distributors, and sales in China grew 8.4%, 1.8% and 16.4%, respectively, in
the first six months of fiscal 2011.

R&D Europe's net sales for the quarter and six months ended December 31, 2010
were $18.6 million and $35.0 million, decreasing 0.7% and 4.3%, respectively,
from the same prior-year periods.  R&D Europe's net sales increased 5.5% and
2.2% for the quarter and six months ended December 31, 2010 when measured at
currency rates in effect in the comparable prior-year period. Hematology net
sales for the quarter and six months ended December 31, 2010 were $4.6
million and $9.5 million, increases of 7.0% and 6.0% from the comparable
prior-year periods.

Consolidated gross margin for the quarter ended December 31, 2010 increased
$298,000, but decreased $631,000 for the six months ended December 31, 2010
from the same prior-year periods. Biotechnology gross margin increased
$973,000 and $1.8 million for the quarter and six months ended December 31,
2010 as a result of increased net sales partially offset by a decrease in
gross margin percentage. R&D Europe gross margin decreased $564,000 and $2.3
million for the quarter and six months ended December 31, 2010 as compared to
the same prior-year periods.  Approximately $1.2 million and $2.4 million of
the decrease in R&D Europe gross margins, respectively, was the result of
changes in exchange rates used to translate sales in foreign currencies into
U.S. dollars. Approximately 15.0% and 6.4% of consolidated net sales for the
six months ended December 31, 2010 were made in euro and British pound
sterling, respectively.  The average euro exchange rate declined 8.8% and
8.3% against the U.S. dollar for the quarter and six months ended December
31, 2010 (euro:$1.34 and euro:$1.33) compared to the same prior-year periods
(euro:$1.47 and euro:$1.45).  The average British pound sterling exchange
rate declined 3.7% and 4.3% against the U.S. dollar for the quarter and six
months ended December 31, 2010 (British pound:$1.57 and British pound:$1.56)
compared to the same prior-year periods (British pound:$1.63 and British
pound:$1.63).  Excluding the effect of the exchange rate on sales, gross
margins for R&D Europe increased $605,000 and $62,000 for the quarter and six
months ended December 31, 2010.

The consolidated gross margin, as a percentage of net sales, was 77.5% for
both the quarter and six months ended December 31, 2010, compared to 79.7%
and 80.1% for the quarter and six months ended December 31, 2009,
respectively. R&D Europe gross margin percentages for the quarter and six
months ended December 31, 2010 were 51.2% and 49.4% compared to 53.9% and
53.7%.  The decrease was a result of the effect of exchange rate changes on
net sales as discussed above. Biotechnology gross margin percentages were
77.8% and 78.1% for the quarter and six months ended December 31, 2010
compared to 80.0% and 80.5% for the quarter and six months ended December 31,
2009.  The decrease in the Biotechnology gross margin percentage was mainly
the result of changes in product mix and $220,000 additional royalty expense
and royalty initiation fees related to new licensing agreements in the first
quarter of fiscal 2011. Royalty initiation fees in the second quarter of
fiscal 2011 were not material.

Selling, general and administrative expenses for the quarter and six months
ended December 31, 2010 decreased $642,000 (7.1%) and $1.1 million (6.6%)
from the quarter and six months ended December 31, 2009. The decrease in
selling, general and administrative expense for the quarter and six months
resulted primarily from decreased legal expenses, lower printing costs due to
the timing of the printing of the annual Biotechnology catalog and the effect
of the change in exchange rates used to convert foreign expenses to U.S.
dollars.

Research and development expenses for the quarter and six months ended
December 31, 2010 increased $212,000 (3.3%) and $677,000 (5.4%) from the
quarter and six months ended December 31, 2009.  The increase in research and
development expenses is mainly due to increases in personnel and supply costs
associated with the continuous development and release of new high-quality
biotechnology products.

The effective tax rate for the quarter and six months ended December 31, 2010
was 29.6% and 31.0% as compared to 32.6% for both of the same prior-year
periods. The improvement in the effective tax rate in fiscal 2011 was the
result of renewal of the U.S. research and development credit discussed above
and an increase in the deduction for qualified production activities.

Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Such statements involve risks and
uncertainties that may affect the actual results of operations. The following
important factors, among others, have affected and, in the future, could
affect the Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
general economic conditions, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in our press releases due to
new information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                   *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854


                         TECHNE CORPORATION
                CONSOLIDATED STATEMENTS OF EARNINGS
               (In thousands, except per share data)
                            (Unaudited)

                                      QUARTER ENDED     SIX MONTHS ENDED
                                   ------------------  ------------------
                                   12/31/10  12/31/09  12/31/10  12/31/09
                                   --------  --------  --------  --------
Net sales                           $67,708   $65,521  $135,653  $132,055
Cost of sales                        15,218    13,329    30,459    26,230
                                   --------  --------  --------  --------
Gross margin                         52,490    52,192   105,194   105,825
                                   --------  --------  --------  --------
Operating expenses:
 Selling, general and
  administrative                      8,365     9,007    15,917    17,045
 Research and development             6,603     6,391    13,222    12,545
 Amortization of intangible assets      171       240       341       480
                                   --------  --------  --------  --------
   Total operating expenses          15,139    15,638    29,480    30,070
                                   --------  --------  --------  --------
Operating income                     37,351    36,554    75,714    75,755

Other income (expense):
 Interest income                      1,020     1,156     1,867     2,324
 Other non-operating expense, net      (698)   (1,011)     (955)   (1,673)
                                   --------  --------  --------  --------
   Total other (expense) income         322       145       912       651
                                   --------  --------  --------  --------
Earnings before income taxes         37,673    36,699    76,626    76,406
Income taxes                         11,139    11,978    23,719    24,913
                                   --------  --------  --------  --------
Net earnings                        $26,534   $24,721  $ 52,907  $ 51,493
                                   ========  ========  ========  ========
Earnings per share:
 Basic                             $   0.72  $   0.66  $   1.43  $   1.38
 Diluted                           $   0.71  $   0.66  $   1.42  $   1.38

Weighted average common
 shares outstanding:
 Basic                               37,093    37,252    37,066    37,248
 Diluted                             37,156    37,353    37,131    37,346



                           TECHNE CORPORATION
                     CONSOLIDATED BALANCE SHEETS
                           (In thousands)
                             (Unaudited)

                                               12/31/10   6/30/10
                                               --------  --------
ASSETS
Cash and equivalents                           $135,875  $ 94,139
Short-term available-for-sale investments        58,987    44,672
Trade accounts receivable                        28,228    30,850
Other receivables                                 1,986     1,532
Inventory                                        13,736    13,737
Other current assets                             14,748    16,110
                                               --------  --------
  Current assets                                253,560   201,040
                                               --------  --------

Available-for-sale investments                  158,666   171,171
Property and equipment, net                      95,096    97,400
Goodwill and intangible assets, net              26,771    27,112
Other non-current assets                         21,515    22,093
                                               --------  --------
  Total assets                                 $555,608  $518,816
                                               ========  ========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities                            $ 13,672  $ 17,024
Stockholders' equity                            541,936   501,792
                                               --------  --------
  Total liabilities and stockholders' equity   $555,608  $518,816
                                               ========  ========

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>seg12-10.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                SEGMENT INFORMATION
                           TECHNE CORPORATION AND SUBISIDARIES
                    (in thousands of $'s, except per share data)

                                                        Increase (Decrease)
                               Fiscal 2011               From Fiscal 2010
                     --------------------------------- ---------------------
                      First  Second          Percent   First   Second
                       Qtr.   Qtr.     YTD   Of Sales   Qtr.    Qtr.    YTD
                     ------  ------  ------- --------- ------  ------ ------
Sales                67,945  67,708  135,653   100%     1,411   2,187  3,598
Cost of sales        15,241  15,218   30,459    22%     2,340   1,889  4,229
                     ------  ------  ------- --------- ------  ------ ------
Gross margin         52,704  52,490  105,194    78%      (929)    298   (631)

Gross margin
 percentage           77.6%   77.5%    77.5%

SG&A expense          7,552   8,365   15,917    12%      (486)   (642)(1,128)
R&D expense           6,619   6,603   13,222    10%       465     212    677
Amortization expense    170     171      341     --       (70)    (69)  (139)
Interest income        (847) (1,020)  (1,867)   (1%)      321     136    457
Other non-operating
 ex., net               257     698      955     1%      (405)   (313)  (718)
                     ------  ------  -------  -------- ------  ------ ------
                     13,751  14,817   28,568    22%      (175)   (676)  (851)
                     ------  ------  -------  -------- ------  ------ ------
Earnings before
 income taxes        38,953  37,673   76,626    56%      (754)    974    220
Income taxes         12,580  11,139   23,719    17%      (355)   (839)(1,194)
                     ------  ------  -------  -------- ------  ------ ------
                     26,373  26,534   52,907    39%      (399)  1,813  1,414
                     ======  ======  =======  ======== ======  ====== ======
Diluted earnings
 per share             0.71    0.71

Weighted average
 diluted shares
 outstanding         37,107  37,156




                                 BIOTECHNOLOGY  (1)
                               (in thousands of $'s)

                                                        Increase (Decrease)
                               Fiscal 2011               From Fiscal 2010
                     --------------------------------- ---------------------
                      First  Second          Percent   First  Second
                       Qtr.   Qtr.     YTD   Of Sales   Qtr.    Qtr.   YTD
                     ------  ------  ------- --------- ------  ------ ------
Sales                54,141  52,652  106,793   100%     2,445   1,949  4,394
Intersegment sales   (7,491) (8,217) (15,708)             177      65    242
                     ------  ------  -------           ------  ------ ------
                     46,650  44,435   91,085            2,622   2,014  4,636

Cost of sales        11,689  11,665   23,354    22%     1,804   1,539  3,343
Intersegment sales   (7,578) (8,251) (15,829)              20    (498)  (478)
                     ------  ------  ------- --------  ------  ------ ------
                      4,111   3,414    7,525            1,824   1,041  2,865

Gross margin         42,539  41,021   83,560    78%       798     973  1,771

Gross margin
 percentage           78.4%   77.8%    78.1%

SG&A expense          4,583   4,780    9,363     9%      (151)   (276)  (427)
R&D expense           6,421   6,379   12,800    12%       465     189    654
Amortization expense    170     171      341     --       (70)    (69)  (139)
Interest income        (581)   (715)  (1,296)   (1%)      190      57    247
Exchange loss/gain       (8)    (10)     (18)    --       (10)    (11)   (21)
                     ------  ------  ------- --------  ------  ------ ------
                     10,585  10,605   21,190    20%       424    (110)   314
                     ------  ------  ------- --------  ------  ------ ------
Pretax result        31,954  30,416   62,370    58%       374   1,083  1,457
                     ======  ======  ======= ========  ======  ====== ======

(1)	Includes R&D Systems' Biotechnology Division, BiosPacific, Inc.
and R&D China



                              R&D SYSTEMS EUROPE
                         (in thousands of Br. pounds)

                                                        Increase (Decrease)
                               Fiscal 2011               From Fiscal 2010
                     --------------------------------- ---------------------
                      First  Second          Percent   First  Second
                       Qtr.   Qtr.     YTD   Of Sales   Qtr.    Qtr.   YTD
                     ------  ------  ------- --------- ------  ------ ------
Sales                10,571  11,767   22,338   100%      (310)    305     (5)
Cost of sales         5,561   5,742   11,303    51%       500     454    954
                     ------  ------  ------- --------- ------  ------ ------
Gross margin          5,010   6,025   11,035    49%      (810)   (149)  (959)

Gross margin
 percentage           47.4%   51.2%    49.4%

SG&A expense          1,188   1,274    2,462    11%        (3)    (44)   (47)
Interest income         (52)    (65)    (117)   (1%)       35      14     49
Exchange loss/(gain)   (323)     58     (265)   (1%)     (234)     (3)  (237)
                     ------  ------  ------- --------- ------  ------ ------
                        813   1,267    2,080     9%      (202)    (33)  (235)
                     ------  ------  ------- --------- ------  ------ ------
Pretax result         4,197   4,758    8,955    40%      (608)   (116)  (724)
                     ======  ======  ======= ========= ======  ====== ======


                              R&D SYSTEMS EUROPE
                             (in thousands of $'s)

                                                        Increase (Decrease)
                               Fiscal 2011               From Fiscal 2010
                     --------------------------------- ---------------------
                      First  Second          Percent   First  Second
                       Qtr.   Qtr.     YTD   Of Sales   Qtr.    Qtr.   YTD
                     ------  ------  ------- --------- ------  ------ ------
Sales                16,391  18,645   35,036    100%   (1,447)   (130)(1,577)
Cost of sales         8,621   9,097   17,718     51%      326     433    759
                     ------  ------  ------- --------- ------  ------ ------
Gross margin          7,770   9,548   17,318     49%   (1,773)   (563)(2,336)

Gross margin
 percentage           47.4%   51.2%    49.4%

SG&A expense          1,842   2,017    3,859     11%     (110)   (142)  (252)
Interest income         (81)   (103)    (184)    (1%)      62      25     87
Exchange loss/(gain)   (497)     97     (400)    (1%)    (352)     (2)  (354)
                     ------  ------  ------- --------- ------  ------ ------
                      1,264   2,011    3,275      9%     (400)   (119)  (519)
                     ------  ------  ------- --------- ------  ------ ------
Pretax result         6,506   7,537   14,043     40%   (1,373)   (444)(1,817)
                     ======  ======  ======= ========= ======  ====== ======



                                HEMATOLOGY
                           (in thousands of $'s)

                                                        Increase (Decrease)
                               Fiscal 2011               From Fiscal 2010
                     --------------------------------- ---------------------
                      First  Second          Percent   First  Second
                       Qtr.   Qtr.     YTD   Of Sales   Qtr.    Qtr.   YTD
                     ------  ------  ------- --------- ------  ------ ------
Sales                 4,904   4,628    9,532    100%      236     303    539
Cost of sales         2,509   2,707    5,216     55%      190     415    605
                     ------  ------  ------- --------- ------  ------ ------
Gross margin          2,395   1,921    4,316     45%       46    (112)   (66)

Gross margin
 percentage           48.8%   41.5%    45.3%

SG&A expense            328     336      664      7%      (42)    (30)   (72)
R&D expense             198     224      422      4%       --      23     23
Interest income         (53)    (66)    (119)    (1%)      19       6     25
                     ------  ------  ------- --------- ------  ------ ------
                        473     494      967     10%      (23)     (1)   (24)
                     ------  ------  ------- --------- ------  ------ ------
Pretax result         1,922   1,427    3,349     35%       69    (111)   (42)
                     ======  ======  ======= ========= ======  ====== ======




                            CORPORATE AND OTHER (2)
                              (in thousands of $'s)

                                              Increase (Decrease)
                               Fiscal 2011     From Fiscal 2010
                     ----------------------- ---------------------
                      First  Second           First  Second
                       Qtr.   Qtr.     YTD     Qtr.   Qtr.   YTD
                     ------  ------  ------- ------  ------ ------
Interest income         132     136      268    (50)    (48)   (98)
Rental income           123     138      261     42      23     65
                     ------  ------  ------- ------  ------ ------
                        255     274      529     (8)    (25)   (33)

SG&A expense            799   1,232    2,031   (183)   (194)  (377)
Other-Building
 expenses               556     531    1,087      8       1      9
Other-Equity
 Investment losses      329     218      547     (9)   (278)  (287)
                     ------  ------  ------- ------  ------ ------
                      1,684   1,981    3,665   (184)   (471)  (655)
                     ------  ------  ------- ------  ------ ------
Pretax result        (1,429) (1,707)  (3,136)   176     446    622
                     ======  ======  ======= ======  ====== ======

(2)	Unallocated corporate expenses and Techne's share of
losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
